• Svenska
  • About Us
    • Overview
    • Our Business
    • Strategy and business model
    • Management
    • Board
  • Our Science
    • Overview
    • Fractalkine program
    • Intellectual Properties
    • Publications
  • Therapeutic Areas
    • Overview
    • Cardiovascular Diseases
    • Cancer
  • Pipeline
    • Overview
    • FRACTAL
    • KANDOVA
    • KAND145
    • Preclinical projects
  • Investors
    • Overview
    • CEO Statement
    • Press Releases
    • The Share
    • Analyst coverage
    • Presentations
    • Financial Calendar
    • Financial Reports
    • Corporate Governance
  • Contact

2022-11-23

See how NHS Foundation Trust presents the KAND567 study (FRACTAL) in patients with myocardial infarction currently ongoing in Newcastle

Follow this link.

Read More

Shortcuts

  • Press Releases
  • Financial Reports
  • Financial Calendar
  • Privacy Policy
  • Contact

Address

Kancera AB
Nanna Svarts väg 4
SE-171 65 Solna, Sweden

Contact

+46 (0)8 50 12 60 80
LinkedIn

Copyright © 2025 Kancera AB. All Rights Reserved. Design by Clavis Communications
The website uses cookies. By clicking on "Accept all", you agree to the use of all cookies. However, you have the opportunity, by clicking "Settings cookies", to give a controlled consent. Read More
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
SAVE & ACCEPT